Cargando…
LINC00152 is a potential biomarker involved in the modulation of biological characteristics of residual colorectal cancer cells following chemoradiotherapy
Concurrent radiotherapy and chemotherapy is a widely used, comprehensive treatment for rectal cancer. By studying the impact of concurrent chemoradiotherapy on the invasion and migration of colorectal cancer (CRC) cells and researching the associated molecular mechanisms, the present study aimed to...
Autores principales: | Chen, Zhengting, Cai, Xinyi, Chang, Li, Xia, Yaoxiong, Wang, Li, Hou, Yu, Li, Lan, Pan, Dingguo, Li, Furong, Liu, Shan, Xiong, Wei, Li, Wenhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835918/ https://www.ncbi.nlm.nih.gov/pubmed/29541183 http://dx.doi.org/10.3892/ol.2018.7833 |
Ejemplares similares
-
Knockdown of long noncoding RNA 00152 (LINC00152) inhibits human retinoblastoma progression
por: Li, Songhe, et al.
Publicado: (2018) -
The prognostic effect of LINC00152 for cancer: a meta-analysis
por: Quan, Fei-Yu, et al.
Publicado: (2017) -
Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer
por: Ou, Chunlin, et al.
Publicado: (2019) -
Knockdown of Long Noncoding RNA 00152 (LINC00152) Inhibits Human Retinoblastoma Progression [Retraction]
Publicado: (2022) -
LINC00152 Knock-down Suppresses Esophageal Cancer by EGFR Signaling Pathway
por: Ding, Yan, et al.
Publicado: (2020)